Pharming Group (OTCMKTS:PHGUF) hit a new 52-week low on Tuesday . The company traded as low as $0.90 and last traded at $0.90, with a volume of 450 shares. The stock had previously closed at $0.94.
A number of equities analysts have weighed in on PHGUF shares. HC Wainwright restated a “buy” rating and issued a $3.10 target price on shares of Pharming Group in a research note on Thursday, August 5th. Zacks Investment Research upgraded Pharming Group from a “sell” rating to a “hold” rating in a research note on Thursday, October 7th.
The firm has a market capitalization of $563.86 million, a P/E ratio of 22.53 and a beta of 1.65. The company has a debt-to-equity ratio of 0.84, a quick ratio of 4.74 and a current ratio of 5.25. The business has a 50 day simple moving average of $1.00 and a two-hundred day simple moving average of $1.13.
About Pharming Group (OTCMKTS:PHGUF)
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.